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S U M M A R Y
Background and Aims: Thickening of basement
membrane in capillaries and small vessels is a well-known
finding and important in the progression of diabetic
microangiopathy. Patients with diabetes mellitus and arterial
hypertension are at higher risk of vascular disease.
Material and methods: To monitor the metabolism of
the basement membrane protein collagen type IV (CIV) in
type 2 diabetes mellitus (T2DM), serum levels of antibodies
to CIV (ACIV) IgG, IgM and IgA were measured using an
ELISA method in 93 patients with type 2 diabetes mellitus
and arterial hypertension (AH) (mean age 61,4±11,3 years,
diabetes duration 9,88±3,12 years; hypertension duration
9,28±4,98). These values were compared to serum antibodies
to CIV in 42 age and sex matched controls. Diabetics were
divided in two groups according to presence- Group 1 (n=67)
or absence- Group 2 (n=26) of microangiopathy.
Results: Patients with T2DM and AH showed
statistically significant higher levels of ACIV IgG  in
comparison to healthy controls (0.30±0.12 vs. 0.21±0.08)
(p=0.0001). Group 1 showed significantly hihger levels of
ACIV IgG  than Group 2 (0.32±0.13vs. 0.24±0.08) (p=0.009)
and healthy controls (0.32±0.13vs. 0.21±0.08) (p=0.0001). ACIV
IgG are statistically significant higher in diabetics with
retinopathy than this without (0.33±0.10 vs. 0.26±0.13)
(ð=0.04). ACIV IgG correlates with diabetes duration (r=0.49);
(p=0.0004), retinopathy (r=0.20); (p=0.05) and BMI (r=-0.24);
(p=0.05). Serum ACIV IgM and IgA levels in patients with
T2DM and AH were lower than these in controls, but the
differences are not statistically significant.
Conclusion: Our study showed a relationship between
elevation of  serum levels of ACIV IgG in diabetics and
development of microangiopathy.
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INTRODUCTION
Clinical manifestations of microvascular and
macrovascular involvement in diabetes include retinopathy,
nephropathy and accelerated atherosclerosis, possible leading
to blindness, renal failure, myocardial infarction, stroke and
limb amputation. These target organ manifestations show
common pathological characteristics underlying all vascular
diseases; however, each complication also has some specific
features depending on the tissue (s) involved, with important
implications for prevention and treatment Mario and Pugliese,
2001 [1]. This diversity is supported by the distinct
epidemiological characteristics of vascular complications,
which occur with a different prevalence in diabetic subjects
Toeller et al. 1999, Laasko 1999 [2]. The incidence of vascular
complications also varies with the site involved.
Macroangiopathy is sometimes present at the time of
diagnosis, particularly in type 2 (non-insulin-dependent)
diabetes mellitus [2], whereas microvascular disease usually
developed several years after the onset of diabetes Krolewski
et al. 1987 [3], Hanefeld et al. 1996 [4]. However, while the
incidence of retinopathy increases with diabetes duration,
that of nephropathy reaches a peak after about 15 years and
declines thereafter. The rate of development and the severity
of vascular injury are also dependent on the individual
background; as a result, some people show only initial
lesions, whereas others progress towards end-stage disease,
despite a similar degree of metabolic derangement.
Arterial hypertension and diabetic vascular
complications are connected with an elevated degradation of
elastic tissue. As a result collagen type IV (CIV) are released
in the circulated blood, which are a pathological stimulus for
an increased production of antibodies to CIV (ACIV). Because
it is very important to find characteristics of pathological
activation of collagen turnover in diabetics we studied diabetic
patients with arterial hypertension who demonstrated
vascular complications.
In diabetes mellitus, thickening of basement
membrane in capillaries and small vessels is a well-known
finding and important in the progression of diabetic
microangiopathy. Collagen type IV is uniquely present in
basement membranes and represents their predominant
structural element Paulsson 1992 [5], Kuhn 1995 [6].
Metabolic alteration of CIV occurs in micro- or
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macrovascular basement membrane of diabetic patients.
Elastin and collagen are the main proteins of vascular
wall. An important factor in the development of vascular wall
alterations is degradation of the extracellular matrix‘s major
protein – collagen Rosenbloom et al., 1993 [7]. Basement
membranes regulate the functions of many cells and mediate
the interactions between different tissues Paulsson, 1992 [5];
Kuhn 1995 [6]. Collagen type IV constitutes the major
component of basement membranes Schuppan and Riecken,
1990 [8]. Measurement of serum antibodies to fragments of
CIV Balashova et al., 2000 [9]; Nicoloff et al., 2002 [10] is now
possible and enables changes to be detected.
Because collagen type IV is uniquely present in
basement membranes and represents their predominant
structural element [6, 8] several immunological methods for
detection of circulating CIV were developed Risteli L.  Et al.
1987 [11]. The detection of circulating CIV in the serum of
diabetic subjects Alland A , Matsumoto E, Nicoloff G [12, 13,
14] shows that the CIV macromolecule is not fully degraded
by collagenases in vivo. These CIV may become a stimulus
for immunocompetent cells and result in the production of
anti-CIV antibodies.
There is data for detection of serum CIV in animals or
humans with arterial hypertension Hasslacher et al., 1987 [15];
Yano et al., 1997 [16]. These CIV fragments may become an
increased stimulus for immunocompetent cells for
pathological production of anti-CIV antibodies.
Investigators Susumu et al, 2003 [20] measured serum
anti-type IV collagen antibody (IgG) in diabetic patients and
they found that serum levels of the anti-type IV collagen
antibody were significantly higher in diabetics than these in
the nondiabetics. However, there was no relationship between
the levels of urinary albumin and the serum levels of anti-
type IV collagen antibody.
We investigated anti-collagen type IV antibodies in
children with essential hypertension and patients showed
significantly higher levels of collagen type IV IgM while
collagen type IV IgG levels were lower than these in controls
Nicoloff et al, 2006 [21].
In the present investigation we studied whether the
serum levels of antibodies (IgG, IgM and IgA) to type IV
collagen are related with the presence of diabetic
microangiopathy. This study establishes normal serum levels
of ACIV in healthy subjects and compares them to these of
patients with diabetes mellitus and arterial hypertension. The
changes observed are correlated with diabetic microvascular
complications.
MATERIAL AND METHODS
Subjects
The experimental group consisted of 93 patients (37
men, 56 women) with type 2 diabetes mellitus and arterial
hypertension (mean age 61,4±11,3 years, diabetes duration
9,88±3,12 years; hypertension duration 9,28±4,98). These
values were compared to serum antibodies to CIV in 42 age
and sex matched controls with no family history of diabetes,
atherosclerosis or emphysema. The controls were equally
distributed to match the diabetic ages. Diabetics were divided
in two groups according to presence- Group 1 (n=67) or
absence- Group 2 (n=26) of microvascular complications
(Table 1). Group 1 cosisted of 39% men and 61% women. Fifty-
five percent were smokers and 45% non-smokers. Group 2
consisted of 42% men and 58% women. Fifty-eight percent
were smokers and 42% non-smokers. Controls consisted of
45% men and 55% women. Twenty-seven percent were
smokers and 73% non-smokers (Table 2). Microalbuminuria
was defined as a persistent urinary albumin excretion rate
(AER) in the range of 20 and 200 µg/min in sterile urine. None
of the patients had a diagnosis of renal disease unrelated to
diabetes during the follow up.
Clinical draft
All patients were residing in the vicinity of the Pleven
University Hospital. Subjects‘ sera were taken from October
2011 to May 2012.  Ethical approval was obtained from the
local research ethics committee and all subjects gave an
informed written consent prior to the study.
Procedure
Serum antibodies (IgG, IgM and IgA) to CIV were
measured by an enzyme-linked immunosorbent assay
(ELISA). In brief, each well of the microtiter plate was
sensitized with 100 µl of 10 µg/ml of human CIV (SIGMA,
USA) at room temperature for 3 h, followed by an overnight
incubation at 4oC. The plate was washed with phosphate-
buffered saline (PBS) containing 0.05% Tween 20 and 1%
bovine serum albumin (BSA, SIGMA, USA). Then, 100 µl
serum sample (diluted 1:10), was placed in each well of a
microtiter plate, and incubated for 1 h at 37oC. After washing
three times, 100 µl of immunoconjugates (anti-human
immunoglobulin peroxidase conjugates (SIGMA, USA) to
heavy chain of IgG, IgM and IgA) were added to each well
for 1 h at 37'C. All immunoconjugates were diluted 1:10,000
with PBS containing 1% BSA and 0.05% Tween 20. The plate
was incubated for 1 h at 37oC. o-Phenylenediamine (0.4 mg/
ml) was added to citrate buffer, and 100 µl of this solution
was added to each well and allowed to react for 30 min. The
reaction was stopped by adding 50 µl 4 M H2SO4 to each
well and the optical density was measured with a Microelisa
Reader 210 (Organon Teknika, Belgium) at a wavelength of
492 nm. Anti-CIV levels greater than the mean±2SD of the
healthy controls were designated positive.
Ophthalmoscopy through dilated pupils was carried
out in all patients with diabetes mellitus to assess the
presence of retinopathy; all patients were examined by the
same ophthalmogist. Hemoglobin A1c was measured using
high-pressure liquid chromatography (normal range 4-6%).
Total serum cholesterol and triglyceride concentrations were
measured by enzyme assay (Boehringer Mannheim,
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using a standard mercury sphygmomanometer, to the nearest
2 mm Hg, in the dominant arm after at least 10 min rest in the
supine position. AER was determined by nephelometry using
a commercial kit containing specific antibody (Behringwerke,
Marburg, Germany).
Statistical analyses
All values are expressed as mean±SD. Statistical
analyses were done using the computer programs EXCEL and
STATGRAPHICS plus for WINDOWS. The Student t-test and
ANOVA were used to assess the differences between groups.
Correlation and regression analyses were also used. The level
of significance was determined as p < 0.05.
RESULTS
Patients with T2DM and AH showed statistically
significant higher levels of ACIV IgG  in comparison to
healthy controls (0.30±0.12 vs. 0.21±0.08) (p=0.0001). Group
1 showed significantly hihger levels of  ACIV IgG  than Group
2 (0.32±0.13 vs. 0.24±0.08) (p=0.009) and healthy controls
(0.32±0.13 vs. 0.21±0.08) (p=0.0001). Group 2 showed higher
levels of ACIV IgG than controls (0.24±0.08 vs. 0.21±0.08)
(p=0,05). ACIV IgG correlates with diabetes duration (r=0.49);
(p=0.0004), retinopathy (r=0.20); (p=0.05) and BMI (r=-0.24);
(p=0.05) (Table 3, Fig. 1). All diabetic patients (n=93) were
divided in two subgroups depending on data for diabetic
retinopathy: patients with retinopathy (n=20) and patients
without retinopathy (n=73) according to European
Association for the Study of Diabetes (EASD) Classification.
Levels of ACIV IgG are statistically significant higher in
diabetics with retinopathy than this without (0,33±0,10 vs.
0,26±0,13) (ð=0.04) (Table 4, Fig. 2).
Serum ACIV IgM and IgA levels in patients with T2DM
and AH were lower than these in controls, but the differences
are not statistically significant (Table 5 and 6).
DISCUSSION
Epidemiological studies have shown a strong
relationship between obesity and cardiovascular disease, and
between obesity and specific cardiovascular risk factors such
as hypertension and diabetes mellitus. In diabetic patients
morbidity and mortality are mainly related to the presence of
late complications, namely macro- and microangiopathy.
Diabetes mellitus (both Type 1 and Type 2) is a major risk
factor for cardiovascular disease. In the Framingham Study,
the risk of cardiovascular disease was doubled by the
presence of diabetes The Framingham study 1979 [17].
Collagens are known to be immunogenic in animals,
and antibodies to various collagens are present in human
serum in several diseases, particularly those of autoimmune
origin Moreland et al., 1991 [18]; Yang et al., 1993 [19];
Daskalova et al., 1997 [22]. The detection of serum CIV in
animals or humans with arterial hypertension Hasslacher et
al., 1987 [15]; Yano et al., 1997 [16] shows that CIV
macromolecule is not fully degraded by collagenases in vivo.
These CIV fragments may become an increased stimulus for
immunocompetent cells for pathological production of anti-
CIV antibodies. Changes in the levels and pattern of
antibodies to CIV may occur with time.
Type IV collagen, which is one of the major
constituents of basement membranes and fibrous tissue, is
composed of a 7S collagen domain formed by four
aminoterminal ends linked together in an antiparallel
arrangement, and a globular carboxyterminal cross linking
domain Sato et al., 1997 [23].  Four or five collagen molecules,
lenghtwise disposed and linked with glycoproteins, form
collagen microfibrile Stanley RG, 2009 [24]. Collagen
catabolism is not fully studied rather than its synsthesis
Labasse A, 2007 [25]. Collagen catabolism is a complex and
multistage process, running not only at intracellular level, but
also at extracellular matrix. Intracellular collagen destruction
starts with activation of highly specific collagenase, which
interacts with collagen molecules Weis et al, 2001 [26].
The object of the study of Yano et al. 1997 [16] was to
evaluate the serum 7S domain of type IV collagen (7S-
collagen) levels in patients with essential hypertension and
in type 2 diabetic patients with or without hypertension and
to investigate the relationship between the type IV collagen
metabolism and the arterial blood pressure. Serum 7S-collagen
levels in 18 patients with essential hypertension were
significantly higher than in 24 normal subjects. There was a
significant correlation between the serum 7S-collagen levels
and the systolic blood pressure in cases with essential
hypertension. In a recent study we measured levels of ACIV
antibodies in patients with diabetes mellitus and arterial
hypertension. Patients with microvascular complications
showed significantly higher levels of ACIV IgG in comparison
with other groups. Patients with type 2 diabetes mellitus are
at high risk of diabetic microangiopathy and vascular disease.
The angiopathic complications usually developed after
several years of type 2 diabetes Klein et al. 1984 [27].  In the
present study, we found a significant relationship between
serum levels of ACIV IgG and development of diabetic
retinopathy.
One possible explanation is that the first
immunoglobulin synthesised during the early phase of a
pathologically activated immune response is IgM. The
immune system then switches on to producte IgG. The
elevation of ACIVAbs of the IgM is therefore the first
indicator of the pathological turnover of collagen and the
development of microvascular complications. Since the cells
responsible for the cell-mediated immune response
(phagocytes, T-effector cells, NK-cells, etc) have more
receptors for the Fc-fragments of IgM, they will react
preferentially with immobilized and soluble immune complexes
formed with IgM ACIV Abs. The presence of ACIV Abs could
lead to a variety of pathological processes including immune
complexes formation.
We found that ACIV IgG are statistically significant318 / J of IMAB. 2012, vol. 18, book 3 /
higher in diabetics with retinopathy. Probably, patients
developed microangiopathy before our detection and they are
not in the very early phase of microvascular disease. The
elevation of anti-CIV of IgG type is therefore the next indicator
of the pathological turnover of CIV.
There is evidence that proteins, including
immunoglobulins, accumulate in the matrix lining the walls of
small blood vessels in diabetic subjects Brownlee et al. 1983
[28]. IgG binds preferentially to basement membranes, which
contain AGE Brownlee et al. 1993 [29]. Prolonged
hyperglycaemia results in irreversible cross-linkage of
collagen containing AGE Airaksinen et al. 1993 [30].
Immunoglobulins bind to collagen-AGE complex, increasing
attachment sites for other proteins and expanding the matrix.
Macrophages react with new epitopes on CIV molecule (CIV
with AGE) and release monokines, tumor necrosis factor and
interleukin-1. The last is an increased non-specific
pathological stimulus for production of more anti-CIV IgG,
which will react with the new epitopes and may be, will cross-
react with “normal “epitopes of CIV molecule. Glycation of
basement membrane CIV is a major process leading to diabetic
microvascular complications. Increased synthesis or
increased degradation could cause the elevated serum levels
of CIV which are strong pathological stimulus for production
of specific antibodies found in our study, mainly in the
patients with retinopathy.
S. Tisheva founds that in pre-hypertension patients
compared to healthy persons, quantities of elastin
degradation peptides were significantly increased. This is
a character of an accelerated elastolisa, and the changes
happen before hypertension determination. In modarate
arterial hypertension persons, elastin turnover is
disbalanced. Increased EDP quantities and high levels of
anti-elastin antibodies can be stated. AH patients compared
to pre-hypertension patients and controls, the constellation
of significantly higher EDP quantities and IgA-antielastin
antibodies levels, of IgA-collagen type IV antibodies, of IgG
collagen type I and of IgG collagen type III antibodies, is a
destroyed integrity sign of fibril structures of vessel wall,
2004 [34].
E. Mekenyan investigates elastin and collagen
turnover in patients with metabolic syndrome and founds
correlation between anti-elastin, anti-tropoelastin and
collagen type IV IgG antibodies and serum triglycerides
levels and correlation between anti-AGEs IgG and IgM and
triglycerides, which prooves association between vascular
aging and athergenic dyslipidemia, characterising metabolic
syndrome, 2012 [35].
In our study we found increased serum levels of anti-
CIV IgG in diabetics with retinopathy. These findings are
supported by the results of Balashova et al. 2000 [11] among
patients with preclinical, nonproliferative, preproliferative, and
proliferative diabetic retinopathy. The authors found that
diabetic retinopathy is characterized by a notable increase in
antibody-dependent immune response, associated with
appearance of antibodies to collagen of the II and IV types
in the lachrymal fluid and serum, with the “local” reactions
predominating. The level of reactions of cellular autoimmune
response (tumor necrosis factor-alpha) and cell-to-cell
reactions in the lachrymal fluid and serum was low. According
to the authors increased level of circulating immune complexes
in the serum and almost complete absence of free antibodies
to collagen in the blood may be indicative of formation of
pathogenic immune complexes precipitating on vascular walls
and in other tissues.
ACIV IgG antibodies showed a significant relationship
to diabetes duration and BMI. The elevated mean levels of
triglycerides and total cholesterol, out of the normal range,
found during the study correlate with the development of
diabetic vascular complications as described Steiner, 1997 [31].
It is well known that hypertriglyceridaemia is the most
common abnormalities in poorly controlled diabetes.
In our study it was not possible to detect the
“active” phase of vascular disease, because of patients‘
diabetes duration 9,88±3,12 years. During this “active”
phase the levels of IgM ACIV were probably elevated, while
during the chronic phase the levels of this type of ACIV
antibody were decreased and only the level of ACIV IgG
was increased.
Our study showed a relationship between serum
levels of ACIV IgG and development of diabetic retnopathy.
The presence of ACIV antibodies could lead to a variety of
pathological processes including immune complexes
formation, complement activation and K cell-mediated
antibody-dependent cell-mediated cytotoxicity (ADCC)
activation, all of which may contribute to the progression
of collagen destruction of arterial wall. Furthermore, collagen
antigen present at the damaged arterial sites retains
selectively antigen specific T- Peterszegi et al. 1997 [32, 33]
and B-lymphocytes which would aggravate the response.
Identification of markers would allow more
aggressiveness in the achievement of tight glycaemic control
and search for initial lesions in those patients who are
predisposed to complications than in those who are not. The
understanding of the relation between hyperglycemia, the
altered pattern of expression of various mediators and the
dysregulated vascular remodeling at the level of the target
tissue would allow design of therapeutic approach targeted
to the individual tissue and to the relevant biochemical,
functional and structural alterations.
In conclusion, our results suggest an association
between levels of ACIV IgG and the development of vascular
wall lesions. Elevation of ACIV IgG  may indicate increased
collagen degradation and development of microvascular
complications. However, a larger study is necessary for
clarification of these possibilities./ J of IMAB. 2012, vol. 18, book 3 / 319
Table 1. Clinical data of patients with T2DM and AH
CLINICAL DATA Group 1 Group 2 Controls
Age 62,5±12,58  60,4±8,4  58,9±7,56
Gender (M/F) 26/41 11/15 10/12
Mean diabetes duration 9,30±5,36 9,16±7,59  N/À
Mean hypertension duration 9,50±7,63 8,68±7,26  N/A
HbA1c *7,63±2,03 7,27±1,63  N/A
SBP (mmHg) 142,83±18,05 140,58±20,51 114,29±15,74
DBP (mmHg) 82,23±11,52 81,35±11,96 72,5±10,4
BMI 29,62±4,99 28,42±3,96 22,61±2,27
TCL (mmol/l) *5,26±1,40 5,18±0,93 3,99±0,65
HDL (mmol/l) *0,88±0,30 0,93±0,30 0,96±0,20
LDL (mmol/l) 3,18±1,19 3,16±1,09 2,43±0,64
TGL (mmol/l) 2,91±1,68 2,53±1,49 1,31±0,61
Insulin dose (U/kg/24h) 2,57±0,52 2,03±0,93  N/A
MAU (µg/min) *78,94±52,87 8,53±4,69  N/A
MAU (n=43)  - 
Retinopathy (n=20) -
Neuropathy (n=4) -
Smokers 37/67 15/26 16/42
Number 67 26 42
Group 1- patients with microvascular complications (n=67 ); Group 2- patients without microvascular complications
(n= 26);   Controls (n=42)       All Data are Mean ±SD
Table 2.  Percentage of smokers on groups
Group 1 Group 2 Controls
Men Smokers  Men Smokers Men Smokers
39% 55% 42% 58% 45% 27%
Women Non-smokers Women Non-smokers Women Non-smokers
61% 45% 58% 42% 55% 73%
Table 3. Serum ACIV IgG in patients with T2DM and AH
Groups ACIV IgG (ng/ml) Comparison
Mean ±SD Group 1 Group 2 All diabetics
All diabetics 0.30±0.12 NS P=0.01 -
Group 1 0.32±0.13 - P=0.009 NS
Group 2 0.24±0.08 P=0.009 - P=0.01
Controls 0.21±0.08 P=0.0001 P=0.05 P=0.0001320 / J of IMAB. 2012, vol. 18, book 3 /
Fig. 2. ACIV IgG are statistically significant higher
in diabetics with retinopathy than this without (ð=0.04).
Fig. 1. Serum ACIV IgG in patients with T2DM and
AH
Table 4. Serum ACIV IgG in patients with T2DM and AH. Patients are divided in two subgroups depending on data
for diabetic retinopathy
ACIV IgG  (ng/ml) Comparison
(With) (Without)
With retinopathy
(n=20) 0.33±0.10 - P=0.04
Without retinopathy
(n=73) 0.26±0.13 P=0.04 -
Table 5.  Serum ACIV IgM in patients with T2DM and AH
Groups ACIV IgM (ng/ml) Comparison
Mean ±SD Group 1 Group 2 All diabetics
All diabetics 0.18±0.07 NS NS -
Group 1 0.19±0.01 - NS NS
Group 2 0.17±0.05 NS - NS
Controls 0.21±0.04 NS NS NS
Table 6. Serum ACIV IgA in patients with T2DM and AH
Groups ACIV IgA (ng/ml) Comparison
Mean ±SD Group 1 Group 2 All diabetics
All diabetics 0.15±0.03 NS NS -
Group 1 0.13±0.02 - NS NS
Group 2 0.11±0.07 NS - NS
Controls 0.17±0.06 NS NS NS/ J of IMAB. 2012, vol. 18, book 3 / 321
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